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Introduction: Dextrose may be used during cardiac arrest resuscitation to prevent or reverse hypoglycemia. However,
the incidence of dextrose administration during cardiac arrest and the association of dextrose administration with
survival and other outcomes are unknown.
Methods: We used the Get With The Guidelines®-Resuscitation national registry to identify adult patients with an
in-hospital cardiac arrest between the years 2000 and 2010. To assess the adjusted effects of dextrose administration
on survival, we used multivariable regression models with adjustment for multiple patient, event, and hospital
characteristics. We performed additional analyses to examine the effects of dextrose on neurological outcome
and return of spontaneous circulation.
Results: Among the 100,029 patients included in our study, 4,189 (4.2%) received dextrose during cardiac arrest
resuscitation. The rate of dextrose administration increased during the study period (odds ratio 1.11, 95% confidence
interval (CI) 1.09-1.12 per year, P <0.001). Patients who received dextrose during resuscitation had lower rates of survival
compared with patients who did not receive dextrose (relative risk 0.88, 95% CI 0.80-0.98, P = 0.02). Administration of
dextrose was associated with worse neurological outcome (relative risk 0.88, 95% CI 0.79-0.99, P = 0.03) but an
increased chance of return of spontaneous circulation (relative risk 1.07, 95% CI 1.04-1.10, P <0.001).
Conclusions: In this dataset, the administration of dextrose during resuscitation in patients with in-hospital cardiac
arrest was found to be associated with a significantly decreased chance of survival and a decreased chance of good
neurological outcome.Introduction
In-hospital cardiac arrest (IHCA) is one of the leading
causes of death in the United States, with an incidence
of over 200,000 patients per year and a mortality rate of
more than 75% [1]. Over the past decade, there have
been enhancements to cardiac life support interventions,
increased quality-improvement efforts, and improved* Correspondence: mdonnino@bidmc.harvard.edu
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rate for IHCA patients remains extremely high [1,3,4].
In 2005, the American Heart Association guidelines
for advanced cardiac life support (ACLS) [5] listed
hypoglycemia as a reversible cause of cardiac arrest but
removed it upon the publication of the current 2010
ACLS guidelines [6]. Pre-2005 editions of the ACLS
guidelines have never included hypoglycemia as a reversible
cause of cardiac arrest, and the provision of dextrose during
cardiac arrest in the absence of confirmed hypoglycemia is
not suggested in the current guidelines [7]. To date, the
current 2010 ACLS guidelines recommend the use of
dextrose with insulin to treat severe hyperkalemia and
suggest that insulin with dextrose can be considered forhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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discourage the use of dextrose for any other condition [6,8].
The use of dextrose in cardiac arrest has not been
adequately studied in the clinical setting, and the
incidence of dextrose administration remains unknown
[9]. Experimental evidence has suggested that dextrose
administration might be harmful. Animal studies have
shown that administering dextrose before, during, or after
cardiac arrest leads to higher rates of mortality and worse
neurological outcome [10-12]. In a study using pigs,
hyperglycemia prior to cardiac arrest was associated with
increased ischemic brain injury and increased markers of
cerebral injury [13]. Similarly, human studies have shown
that higher post-arrest blood glucose levels are associated
with increased mortality and poor neurological outcome
[14-20]. Hyperglycemia is also an independent predictor
of mortality in myocardial infarction and stroke [21,22].
We hypothesized that the administration of dextrose
during cardiac arrest resuscitation would be associated
with higher post-arrest mortality and worse neurological
outcome. To test this hypothesis, we used a large
national registry of IHCAs to establish the rate of
dextrose administration during cardiac arrest. We then
compared the survival with discharge of patients who
received dextrose with patients who did not receive
dextrose during cardiac arrest resuscitation. Secondarily,
we assessed the association between dextrose administra-




The Get With The Guidelines®-Resuscitation (GWTG-R)
registry, formerly known as the National Registry of
Cardiopulmonary Resuscitation, is a national, prospective,
quality-improvement registry of IHCAs and is sponsored
by the American Heart Association. The GWTG-R design
for data collection and reliability has been described
previously in detail [23]. In brief, trained research
personnel at participating hospitals collect data on all
IHCA patients who do not have prior do-not-resuscitate
orders or cardiopulmonary resuscitation events that began
outside of the hospital. Cardiac arrest is defined as pulse-
lessness requiring chest compressions or defibrillation or
both, with a hospital-wide or unit-based emergency
response by acute care facility personnel. Cases are identi-
fied and data are extracted from cardiac arrest flow sheets,
reviews of hospital paging system logs, routine checks of
code carts, pharmacy drug records, and hospital billing
charges for resuscitation medication [23].
To facilitate uniform reporting across hospitals, the
registry employs Utstein-style templates for cardiac
arrest, a set of standardized reporting guidelines used to
define patient variables and outcomes [24,25]. Furtherintegrity of the data is ensured through rigorous certifica-
tion of data entry personnel and the use of standardized
software that checks the data for completeness and accur-
acy [26]. All participating hospitals are required to comply
with local regulatory guidelines. Because data are used
primarily at the local site for quality improvement, sites
are granted a waiver of informed consent under the
common rule. The institutional review board at Beth
Israel Deaconess Medical Center (Boston, MA, USA)
reviewed the present study and determined that it did not
meet the federal definition of human subject research.
Study population
Our cohort study includes data submitted to the
GWTG-R registry between January 2000 and September
2010. We included all patients 18 years or older. To
secure the accuracy of the data, we excluded cases from
hospitals with high rates of missing data, defined as an
average rate of missing data for variables in our model of
more than 10%. We also excluded cases from hospitals
with fewer than five cases per year, fewer than a total of 20
reported cases, less than one year of reporting, and cases
with missing hospital data. Non-index events and events
without initiation of cardiopulmonary resuscitation were
excluded. Patients with missing data on dextrose adminis-
tration and patients who simultaneously received dextrose
and insulin (recommended treatment for presumed hyper-
kalemia) were also excluded (Figure 1).
Study outcomes
The exposure variable, administration of dextrose, was
defined as any administration of a dextrose bolus without
concurrent administration of insulin during the cardiac
arrest. Dextrose administration before or after the event
was not included. The primary outcome of interest was
survival to discharge. Secondary outcomes were good
neurological outcome at the time of hospital discharge
and ROSC, defined as at least 20 minutes with a palpable
pulse. Neurological outcome was assessed with the use of
the cerebral performance category (CPC) score, in which
a CPC score of 1 indicates mild or no neurological deficit,
2 moderate cerebral disability, 3 severe cerebral disability,
4 coma or vegetative state, and 5 brain death [27]. A CPC
score of 1 or 2 was considered a good neurological
outcome, and a CPC score of 3 to 5 or death was
considered a bad neurological outcome.
Statistical analysis
The study population was characterized by using descrip-
tive statistics. Categorical variables are provided in fre-
quencies and continuous variables in means with standard
deviation or medians with interquartile range (IQR),
depending on the normality of the data. Differences
between variables were evaluated by using chi-squared
Figure 1 Study population. In total, 98,230 cardiac arrests were excluded, leaving 100,029 cardiac arrests from 349 hospitals. CPR, cardiopulmonary
resuscitation; IHCA, in-hospital cardiac arrest.
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tests for continuous variables. The change in incidence of
dextrose administration over time (treated as a continuous
variable for this analysis) was assessed by using unadjusted
logistic regression, and the result is presented as an odds
ratio (OR) with 95% confidence interval (CI).
To assess the independent association between dextrose
administration during cardiac arrest resuscitation and sur-
vival to discharge, we used multivariable regression models
with generalized estimating equations with an exchangeable
(compound symmetry) correlation matrix to account for
hospital clustering. Since the outcome was not rare (>10%),
we used modified Poisson regression models with robust
variance estimates to estimate risk ratios (RRs) as described
by Zou [28] and Zou and Donner [29] and previously used
in this cohort [2,30]. In our model, we adjusted for age,
gender, race, coexisting conditions, arrest characteristics
(including presumed cause of the arrest and initial rhythm),
interventions during the arrest, and selected hospital
characteristics (see Additional file 1: Table S1 for a
full list of variables). Year of arrest was entered in the
model as a categorical variable with year 2000 as the
reference. All variables were chosen a priori on the
basis of prior work and clinical reasoning [2,26,30-33].
Similar multivariate regression models were used to
analyze secondary outcomes. Results from the multivari-
able regression models are reported as RRs with 95% CIs.The rate of missing data in the study cohort was low
(<1%) except for race (7.0%), initial rhythm (5.7%),
downtime (4.7%), time of day (1.3%), and neurological
outcome (2.6%). To account for missing data, we imputed
the median value for patients of the same gender for all
observations with missing covariates. We then did the
multivariate logistic regression including the imputed
values for those missing covariates. The point estimates
for the variables included in the models with and
without imputation were similar, and thus we have
reported non-imputed models.
To determine the association between dextrose adminis-
tration and post-resuscitation survival, we conducted a
subgroup analysis on all patients who achieved ROSC. We
performed a sensitivity analysis in which all patients with
a downtime (see Additional file 1: Table S1 for a precise
definition) of 5 minutes or less (to avoid confounding by
potential survival bias) or with more than 10 minutes of
downtime were excluded (to avoid the possibility that
administration of glucose was purely a function of longer
downtime). To further ensure that the patients who
received dextrose were not being treated for hyperkalemia,
we conducted a subgroup analysis excluding all patients
who received calcium chloride or calcium gluconate. To
test for effect modification, we conducted a pre-planned
stratified analysis based on coexisting diabetes. We per-
formed a number of post hoc analyses to assess other
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terms in the main model between dextrose administration
and the following: cardiac cause of the arrest defined as
active/evolving myocardial infarction or arrhythmia
(yes/no), cardiac reason for admission (yes/no), no
coexisting sepsis or hepatic insufficiency (yes/no) (that is,
potential reasons for hypoglycemia in a non-diabetic
patient), location of the arrest (ICU versus non-ICU),
and coexisting metabolic/electrolyte abnormalities
within 4 hours of the arrest (inclusive of hypoglycemia), or
presumed cause of the arrest as metabolic/electrolyte
abnormality (yes/no).
To assess the robustness of our findings, we performed
a propensity-matched adjusted analysis to test the asso-
ciation between glucose administration and each out-
come. For the propensity-matched analysis, we used the
imputed dataset and included all variables that had
been included as independent variables in the primary
analysis as well as hospital center. Next, we per-
formed a 1:3 propensity score match between patients
administered and not administered glucose by using
an algorithm match caliper radius of 0.10 around the
propensity score. We confirmed that the matched
groups were balanced by ensuring that the standard-
ized differences between groups for each covariate
were less than 10. There was a small but statistically
significant difference between cases and controls for three
variables (Additional file 2: Table S2). With the 1:3
propensity-matched dataset, associations between glu-
cose administration and outcomes were assessed with
the Cochran-Mantel-Haenszel test to ensure compari-
son between matched pairs. Using these three vari-
ables, we performed an adjusted and unadjusted
conditional logistic regression analysis. There was a less
than 4% change in the point estimates (adjusted versus
unadjusted), and the unadjusted results are presented
here. Results from the propensity-matched analysis are
reported as OR with 95% CIs.
Statistical analyses were conducted with SAS soft-
ware version 9.3 (SAS Institute Inc., Cary, NC, USA). All
hypothesis tests were two-sided, and a P value of less than
0.05 was considered significant.
Results
Characteristics of the study population
In total, 100,029 IHCAs from 349 hospitals were included
in the main analysis (Figure 1). The median age was 69
(IQR 57–79), and 42% were female. Additional patient,
arrest, and hospital characteristics are shown in Tables 1
and 2. Administration of dextrose occurred in 4,173
(4.2%) cardiac arrests. There was a significant increase
in the incidence of dextrose administration from 2000
(2.5%) to 2010 (5.7%) (OR 1.11, 95% CI 1.09-1.12 per year,
P <0.001) (Figure 2).Primary outcome
Eighteen point six percent of patients survived to
hospital discharge. Patients who received dextrose
during cardiac arrest resuscitation had a lower rate of
survival to discharge compared with patients who did
not receive dextrose (RR 0.49, 95% CI 0.44-0.54, P <0.001).
After multivariable adjustment, dextrose was still associ-
ated with a significantly decreased chance of survival to
discharge (RR 0.88, 95% CI 0.80-0.98, P = 0.02) (Figure 3).
See Additional file 3: Table S3 for the full model.
Secondary outcomes
Fifty-eight point two percent of patients achieved ROSC,
and 13.7% of patients with full data had a good neuro-
logical outcome at hospital discharge (an additional 2.6%
survived but had missing data on neurological outcome).
In unadjusted analyses, administration of dextrose was
associated with decreased chance of ROSC (RR 0.92,
95% CI 0.88-0.96, P <0.001) and decreased chance of
good neurological outcome (RR 0.43, 95% CI 0.38-0.49,
P <0.001). After multivariable adjustment, dextrose
administration was associated with an increased chance
of ROSC (RR 1.07, 95% CI 1.04-1.10, P <0.001) and a
decreased chance of good neurological outcome (RR 0.88,
95% CI 0.79-0.99, P = 0.03, Figure 3).
To further characterize the association between
administration of dextrose and post-resuscitation survival,
we conducted a subgroup analysis including only patients
who obtained ROSC. In this subgroup, our multivariable
analysis showed that administration of dextrose was still as-
sociated with both decreased chance of survival to discharge
(RR 0.84, 95% CI 0.77-0.92, P <0.001) and decreased chance
of good neurological outcome (RR 0.84, 95% CI 0.76-0.93,
P = 0.001). In our sensitivity analysis of patients with a
downtime between 5 and 10 minutes, we found that dex-
trose was associated with an increased chance of ROSC (RR
1.06, 95% CI 1.01-1.10, P = 0.008), a strong trend toward
decreased chance of survival (RR 0.83, 95% CI 0.68-1.01,
P = 0.06), and decreased chance of good neurological
outcome (RR 0.78, 95% CI 0.62-0.99, P = 0.04).
We conducted a pre-planned analysis in order to
investigate potential effect modification by coexisting
diabetes (type I or type II). Thirty point six percent
of the overall population had documented diabetes,
and dextrose was more commonly administered in
patients with diabetes than in patients without diabetes
(5.6% versus 3.5%, P <0.001). There was a significant
interaction between dextrose administration and diabetes
status with survival as outcome (P = 0.02) but not with
ROSC (P = 0.46) or good neurological outcome (P = 0.23)
as the outcome measure. In patients with diabetes,
administration of dextrose was not associated with sur-
vival to discharge (RR 0.94, 95% CI 0.83-1.07, P = 0.32),
whereas in patients without diabetes, the administration
Table 1 Characteristics of the study population according to dextrose administration
Characteristic Received dextrose during cardiac arrest P value
No Yes
(n = 95,856) (n = 4,173)
Demographics
Age in years, median (IQR) 69 (57–79) 65 (53–77) <0.001
Sex, number (percentage) 0.03
Female 40,306 (42.1) 1,690 (40.3)
Male 55,550 (58.0) 2,499 (59.7)
Race, number (percentage) <0.001
White 68,474 (76.8) 2,527 (64.8)
Black 17,109 (19.2) 1,208 (31.0)
Other 3,551 (4.0) 165 (4.2)
Type of admission, number (percentage) <0.001
Medical-Non-cardiac 41,798 (43.6) 2,267 (54.3)
Medical-Cardiac 32,031 (35.4) 1,212 (29.1)
Surgical-Non-cardiac 10,877 (11.4) 421 (10.1)
Surgical-Cardiac 6,188 (6.5) 185 (4.4)
Trauma 2,777 (2.9) 73 (1.8)
Other 272 (0.3) 14 (0.3)
Pre-existing conditions, number (percentage)
Cardiac
Arrhythmia 31,414 (32.9) 1,188 (28.5) <0.001
History of MI 15,864 (16.6) 584 (14.0) <0.001
MI this admission 17,148 (17.9) 472 (11.3) <0.001
History of heart failure 20,090 (21.0) 911 (21.9) 0.19
Heart failure this admission 17,091 (17.9) 702 (16.8) 0.08
Non-cardiac
Respiratory insufficiency 40,001 (41.9) 1,672 (40.2) 0.03
Diabetes mellitus 28,759 (30.1) 1,717 (41.2) <0.001
Renal insufficiency 30,784 (32.2) 1,838 (44.0) <0.001
Metastatic/Hematologic malignancy 11,801 (12.4) 471 (11.3) 0.05
Hypotension/Hypoperfusion 26,263 (27.5) 1,107 (26.6) 0.21
Pneumonia 13,015 (13.6) 592 (14.2) 0.30
Baseline depression in CNS function 12,273 (12.8) 564 (13.5) 0.18
Metabolic/Electrolyte abnormality 15,477 (16.2) 974 (23.3) <0.001
Septicemia 14,586 (15.3) 872 (20.9) <0.001
Acute CNS non-stroke event 6,991 (7.3) 314 (7.5) 0.58
Hepatic insufficiency 6,724 (7.0) 431 (10.4) <0.001
Acute stroke 3,686 (3.9) 144 (3.5) 0.18
Major trauma 3,587 (3.8) 104 (2.5) <0.001
CNS, central nervous system; IQR, interquartile range; MI, myocardial infarction.
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vival (RR 0.80, 95% CI 0.69-0.94, P = 0.005) (Figure 4).
After exclusion of patients who received calcium chloride
or calcium gluconate, the association between dextroseadministration and mortality remained (RR 0.88, 95%
CI 0.78-0.98, P = 0.02). None of the other interaction
terms tested (see Methods section) was statistically signifi-
cant, indicating no subgroup differences.
Table 2 Arrest and hospital characteristics according to dextrose administration
Characteristic Received dextrose during cardiac arrest P value
No Yes
(n = 95,856) (n = 4,173)
Location and time of the arrest, number (percentage)
Location <0.001
Floor without telemetry 15,855 (16.6) 1,025 (24.6)
Floor with telemetry 16,710 (17.4) 730 (17.5)
Intensive care unit 45,011 (47.0) 1,597 (38.3)
Emergency department 10,363 (10.8) 544 (13.0)
Other 6,974 (7.6) 276 (6.6)
Time of day <0.001
Day (7 a.m. -10:59 p.m.) 63,897 (67.6) 2,666 (64.5)
Night (11 p.m.-6:59 a.m.) 30,673 (32.4) 1,467 (35.5)
Time of week, number (percentage) 0.30
Weekday (Monday-Friday) 65,269 (68.8) 2,818 (68.0)
Weekend (Saturday-Sunday) 29,642 (31.2) 1,326 (32.0)
Hospital-wide response called, number (percentage) 76,720 (80.0) 3,361 (80.5) 0.40
Characteristic of the arrest
Monitoring, number (percentage) 78,166 (81.6) 3,053 (73.2) <0.001
Witnessed, number (percentage) 78,262 (81.7) 3,050 (73.1) <0.001
First rhythm shockable (VT or VF), number (percentage) 18,340 (20.3) 517 (13.0) <0.001
Mechanical ventilation in place, number (percentage) 27,928 (29.1) 1,103 (26.4) <0.001
Airway inserted during event, number (percentage) 51,028 (53.3) 2,680 (64.2) <0.001
Presumed cause(s) of arrest, number (percentage)
Arrhythmia 56,147 (58.9) 2,215 (53.4) <0.001
Hypotension/Hypoperfusion 37,571 (39.4) 1,596 (38.5) 0.22
Active/Evolving MI 8,919 (9.4) 270 (6.5) <0.001
Acute respiratory insufficiency 37,064 (38.9) 1,670 (40.3) 0.08
Metabolic/Electrolyte abnormality 10,809 (11.4) 860 (20.7) <0.001
Other 7,619 (8.0) 345 (8.3) 0.46
Unknown 10,340 (10.9) 578 (13.9) <0.001
Downtime in minutes, median (IQR) 12 (6–21) 18 (10–27) <0.001
Medications given during the event, number (percentage)
Amiodarone 14,806 (15.5) 703 (16.9) 0.01
Epinephrine 84,336 (88.0) 4,019 (96.3) <0.001
Atropine 67,947 (70.9) 3,490 (83.6) <0.001
Magnesium sulfate 7,156 (7.5) 567 (13.6) <0.001
Lidocaine 10,152 (10.6) 381 (9.1) 0.003
Sodium bicarbonate 43,775 (45.7) 3,111 (74.6) <0.001
Fluid bolus 28,011 (29.2) 1,452 (34.7) <0.001
Calcium chloride/gluconate 20,188 (21.1) 1,955 (46.9) <0.001
Norepinephrine 12,500 (13.0) 675 (16.2) <0.001
Dopamine 23,078 (24.1) 1,037 (24.1) 0.25
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Table 2 Arrest and hospital characteristics according to dextrose administration (Continued)
Hospital characteristics, number (percentage)
Bed size <0.001
1-249 23,450 (24.2) 908 (21.7)
250-499 44,001 (45.9) 1,836 (44.0)
500+ 28,408 (29.6) 1,429 (34.1)
Teaching status <0.001
Major 25,246 (26.3) 1,527 (36.6)
Minor 33,930 (35.3) 1,162 (27.7)
Non-teaching 36,680 (38.2) 1,484 (35.4)
Ownership <0.001
Private 12,247 (12.8) 540 (12.9)
Government 14,407 (15.0) 899 (21.5)
Non-profit 69,202 (72.2) 2,734 (65.5)
Location <0.001
Rural 6,274 (6.5) 216 (5.2)
Urban 89,582 (93.5) 3,957 (94.8)
Geographical location <0.001
North-East 10,484 (10.9) 491 (11.7)
South-East 26,019 (27.1) 1,125 (26.9)
Mid-West 23,539 (21.0) 1,099 (26.9)
South-West 19,998 (20.9) 864 (21.4)
West 15,816 (16.5) 564 (13.5)
IQR, interquartile range; PEA, pulseless electrical activity; VF, ventricular fibrillation; VT, ventricular tachycardia.
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The propensity matching resulted in a successful match
of 4,171 patients administered dextrose to 12,498 pa-
tients who did not receive dextrose. The groups were
well matched on covariates (Additional file 2: Table S2).Figure 2 Incidence of dextrose administration over time.
Percentage of cardiac arrests with dextrose administration over
time. Error bars indicate exact binomial 95% confidence intervals
(CIs). There was a steady increase in the incidence of dextrose
administration from 2000 (2.5%) to 2010 (5.7%) (odds ratio 1.11,
95% CI 1.09-1.12 per year, P <0.001).With our propensity-matched dataset, administration
of dextrose was associated with a significantly de-
creased chance of survival to discharge (OR 0.80,
95% CI 0.71-0.90, P <0.001). Dextrose administration
was likewise associated with a decreased chance of
good neurological outcome (OR 0.79, 95% CI 0.68-0.91,
P = 0.001). However, the association between dextrose
administration and ROSC was not significant when
the propensity-matched analysis was used (OR 1.06,
95% CI 0.99-1.13, P = 0.12).
Discussion
In this large cohort study using the GWTG-R national
database, we examined the association between dextrose
administration and outcomes after cardiac arrest. We
found that the use of dextrose during resuscitation is
independently associated with lower rates of survival and
unfavorable neurological outcomes. These associations
remained significant even after multivariable adjustments
and sensitivity analyses. The association between dextrose
administration and lower rates of survival and unfavorable
neurological outcomes furthermore remained in our
propensity-matched analyses. In our primary analysis,
dextrose administration was associated with slightly
higher rates of ROSC; however, this association was no
Figure 3 The association between dextrose administration and outcome. The association between administration of dextrose and survival
to discharge, neurological outcome, and return of spontaneous circulation (ROSC). Adjusted risk ratios with 95% confidence intervals are shown.
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finding difficult to interpret.
Although we cannot conclude from retrospective
data why clinicians were giving dextrose during cardiac
arrest, we would hypothesize that concern for hypoglycemia
as the cause of arrest was likely a primary reason. Dextrose
may also be administered out of concern that hypoglycemia
is associated with higher mortality and potentially
brain injury [34,35]. In dealing with a high-mortality
event like cardiac arrest, clinicians are motivated to
find and treat any potential reversible cause. With
this in mind, in a truly hypoglycemic patient, the use
of dextrose is probably recommended. However, studies
have shown that hypoglycemia can be easily misdiagnosed
in patients experiencing ischemic injuries. In current
medical practice, a sample of capillary blood taken with a
fingerstick blood glucose test is the quickest method to
assess the possibility of hypoglycemia. However, studiesFigure 4 Dextrose, diabetes status, and survival. The association betwe
by diabetes status. Adjusted risk ratios with 95% confidence intervals are shhave shown that fingerstick blood glucose measurements
are inaccurate in patients in shock [36,37] or cardiac
arrest [38]. However, the use of venous blood with a
bedside glucometer is accurate and could be used if
deemed necessary.
The administration of dextrose in normoglycemic or
hyperglycemic patients can lead to higher blood glucose
levels. Patients with hyperglycemia after cardiac arrest
[14-18] and other ischemic injuries (stroke [39] and head
injury [40,41]) have longer recovery times and worse
neurological outcomes. Traditionally, this elevation in
blood glucose has been assumed to be part of a systemic
stress response. The potential mechanisms behind
elevated blood glucose levels and the association with
poor outcome are not well understood. Prior studies have
suggested that having higher blood glucose levels during
periods of ischemia increases anaerobic metabolism, pro-
motes the conversion of pyruvate into lactate, causesen administration of dextrose and survival to discharge was stratified
own.
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exacerbating cerebral ischemic injury [42-44]. Whether
hyperglycemia plays a causal role in this process or is
simply a marker of a systemic stress response or of
dysfunctional metabolism at the cellular level is not clear.
One randomized study examined the relationship
between dextrose administration after out-of-hospital
cardiac arrest and neurological outcome and found no
difference between the patients receiving 5% dextrose and
those receiving half normal saline [45]. However, the aver-
age dose of dextrose used in this study was low (7 g) com-
pared with the usual bolus dose (50 mL) of 50% dextrose,
which contains 25 g of dextrose. To date, no study has ex-
plored the relationship between the use of a dextrose
bolus during cardiac arrest resuscitation and outcome.
Our subgroup analysis revealed that although the use of
dextrose was associated with higher mortality in non-
diabetic patients, the association was not significant in
patients with diabetes. The resilience of patients with
diabetes to the deleterious effects of acute hyperglycemia
has been documented [17,46]. Having chronically elevated
levels of blood glucose can cause structural and functional
modifications, such as a greater buffering capacity and
lower cerebral pH levels after induced cardiac arrest [47].
Chronic hyperglycemia has also been found to be partially
protective against cerebral hypoxia caused by acute hyper-
glycemia [42]. The underlying mechanism of the potential
protective effects of diabetes on acute hyperglycemia
needs to be clarified in future studies. Another potential
explanation for our findings is the higher rate of true
hypoglycemia in diabetic patients for whom administra-
tion of dextrose would likely be beneficial.
The results of our study should be interpreted in the
context of the following limitations. Even though the
GWTG-R registry has a rigorous training and certification
process and employs standardized definitions, the data
acquired by the registry may contain data integrity and
validity issues. Although the GWTG-R registry is large,
participation is still voluntary and this raises the potential
for selection bias. Also, GWTG-R is a quality-improvement
registry and was not specifically tailored to study the effects
of dextrose in cardiac resuscitation. Given the observational
nature of the present study, we cannot exclude the possibil-
ity that unmeasured or residual confounding remains. We
were unable to identify the reason why dextrose was ad-
ministered, the dosage that was given, and the timing in
which it was administered. In addition, information on
whether patients were receiving dextrose-containing fluid
before or after the event was not available, and glucose
levels were not available for any patients. It is also possible
that dextrose was more likely to be administered in patients
in whom initial resuscitation attempts failed, giving them a
poorer prognosis. However, we believe that we addressed
this potential issue in multiple ways: downtime wasincluded in our multivariable model, and our sensitivity
analyses of cardiac arrests with downtime of between 5 and
10 minutes gave largely similar results as our primary ana-
lyses. Also, potential confounding by intra-arrest variables
such as prolonged downtime or non-adherence to recom-
mended protocols cannot explain the increased chance of
ROSC seen in our primary analysis. The post-cardiac arrest
population is a heterogeneous group. Despite our pre-
defined and post hoc subgroup analyses, there still
could be certain subgroups of patients for whom dex-
trose administration is beneficial. As always, patient
care should be individually tailored to the clinical
situation. Finally, given the exploratory nature of our
analysis, the results should be verified in a prospective
manner or in a dataset with more granular data (that is,
reason for dextrose administration, timing of dextrose
administration, and intra- and post-cardiac arrest glucose
levels) or both before any conclusions regarding clinical
practice can be made.
Conclusions
Although a causal relationship cannot be determined,
our analysis shows that cardiac arrest patients receiving
dextrose during resuscitation have a decreased chance of
survival to hospital discharge and a decreased chance
of good neurological outcome. This association seems
to be driven primarily by an effect in the non-diabetic
population.
Key messages
 The association between dextrose administration
during cardiac arrest and survival is unknown.
 Dextrose is used in approximately 4.2% of all
in-hospital cardiac arrests, with an increasing rate
from 2000 to 2010.
 Patients who received dextrose during resuscitation
had lower rates of survival compared with patients
who did not receive dextrose, although whether this
relationship is causal remains unproven.
 This association was maintained when using
multivariable regression, sensitivity analyses, and a
propensity-matched analysis.
 The association between dextrose administration
and poor survival seems to be driven primarily by an
effect in the non-diabetic population.
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